Earnings Call · Q2 FY2024·2024-08-11

Q2 24EPS -9.09%·Rev n/aQ1 24EPS -22.22%·Rev n/aQ4 23EPS +11.11%·Rev n/aQ3 23EPS +11.11%·Rev n/a⚠ consensus missing

Trevi Therapeutics, Inc. TRVI

Jennifer Good — Chief Executive Officer

Lisa Delfini — Chief Financial Officer

+2.1%1d on move date+1.7% vs SPY3d−3.6%5d−1.8%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TRVI calls or request research access.

More TRVI calls Browse calls Request research access